FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and medicine, specifically to a method for treating a disease or condition, wherein said disease or condition is selected from the group, consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm. Method of treating a disease or condition, wherein said disease or condition is selected from the group consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm, wherein said method comprises administering a combination, the combination comprising an effective amount of compound (A) and an effective amount of compound (B) or a pharmaceutically acceptable salt thereof, wherein compound (A) has the following structure:
wherein R1 is hydrogen;
is selected from the group consisting of substituted
, substituted
and substituted
, where ring B is substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, unsubstituted methyl and unsubstituted ethyl; R2 is
; m is 0 or 1; R3 is unsubstituted C1-C6 alkyl; X is selected from the group consisting of
and
; Y is CH; and compound (B) is a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof; wherein the Bcl-2 inhibitor is selected from the group consisting of venetoclax (ABT-199)
and navitoclax (ABT-263)
or pharmaceutically acceptable salts of any of said.
EFFECT: method described above is more effective in treating said diseases or conditions as compared to the monotherapy.
16 cl, 4 dwg, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2829459C1 |
SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2020 |
|
RU2824583C2 |
3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PHARMACEUTICAL USE THEREOF | 2021 |
|
RU2831014C1 |
SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXANE-2-YL)PYRAZOLO[1.5-A]PYRIMIDINE AND IMIDAZO[1.2-B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2781618C2 |
CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS | 2020 |
|
RU2836016C2 |
Authors
Dates
2025-05-28—Published
2020-12-16—Filed